SPT Labtech’s Acquisition of Apricot Designs Expands Liquid Handling Technologies Portfolio
Through the acquisition, SPT will have the ability to expand its portfolio of liquid handling technologies as part of its larger portfolio of automation solutions for drug discovery, structural biology, genomics, cryo-EM, sample management, and biobanking.
SPT Labtech, an automated instrumentation and consumables designer and developer, has acquired Apricot Designs, a US-based laboratory equipment supplier, in the latter half of January 2021.
Through the acquisition, SPT will have the ability to expand its portfolio of liquid handling technologies as part of its larger portfolio of automation solutions for drug discovery, structural biology, genomics, cryo-electron microscopy, sample management, and biobanking, SPT said in a Jan. 21, 2021 company press release. The agreement will also increase SPT’s global footprint through Apricot’s US and Asia locations.
"We are delighted to welcome Apricot Designs to the SPT Labtech group,” said Patrick Bennett, group CEO at SPT Labtech, in the press release. “The company's liquid handling technology products seamlessly complement our existing portfolio of high-performance positive displacement instruments. The addition reflects our continued commitment to accelerating scientific research by maximizing our customers' productivity. The powerful combination of technologies and application know-how will enable us to streamline end-to-end workflows and serve a wider range of research applications."
"We are delighted to join SPT Labtech, a company with an impressive reputation for creating innovative, automated solutions for life sciences,” added Felix H. Yiu, CEO of Apricot Designs, in the press release. “We are confident that customers will benefit from the partnership's combined product capabilities, industry-leading applications and technical support, and enhanced infrastructure."
Source: SPT Labtech
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
